Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773576 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Risperidone Implants
A Phase 3 study of Schizophrenia, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT02773576: Completed Phase 3 study of Schizophrenia, sponsored by Braeburn Pharmaceuticals.
NCT02773576 is a Phase 3 study of Schizophrenia that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 140 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02773576, a Phase 3 study of Schizophrenia, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
Primary Outcome
The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.
Conditions Studied
Interventions
- DRUG Risperidone implant
Study Locations (1)
California
- Collaborative Neuroscience Network - Garden Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-09 |
| Phase | Phase 3 |
What the finished NCT02773576 record still lists
NCT02773576 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Risperidone implant is the first listed.
NCT02773576 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02773576 about?
NCT02773576 is a clinical study titled "Safety and Tolerability of Risperidone Implants". A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
What is the current status of trial NCT02773576?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2016-04. Estimated completion is 2017-09.
What conditions does trial NCT02773576 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02773576?
The interventions under investigation include: Risperidone implant (DRUG).
Who is sponsoring clinical trial NCT02773576?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02773576 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02773576's enrollment target sits among peer trials
140 111th of 315 higher than 203 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02507141 · 140 participants
Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia